Imatinib Active Not Recruiting Phase 2 Trials for Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase of Disease Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00070499Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia